|
US2021023237A1
|
|
Therapeutic combinations comprising anti-cd123 immunoconjugates
|
|
TW202100557A
|
|
Biparatopic fr-alpha antibodies and immunoconjugates
|
|
WO2020219287A1
|
|
Camptothecin derivatives
|
|
TW202102506A
|
|
Benzodiazepine derivatives
|
|
TW202102270A
|
|
Methods of preparing cell-binding agent-drug conjugates
|
|
TW202033530A
|
|
Methods of preparing cytotoxic benzodiazepine derivatives
|
|
US2020172481A1
|
|
Methods of preparing cytotoxic benzodiazepine derivatives
|
|
WO2020092533A2
|
|
Methods of treatment using anti-cd123 immunoconjugates
|
|
TW202029980A
|
|
Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof
|
|
WO2020014306A1
|
|
Met antibodies and immunoconjugates and uses thereof
|
|
AU2019294510A1
|
|
Immunoconjugates targeting ADAM9 and methods of use thereof
|
|
AR115624A1
|
|
IMMUNOCONJUGATES TARGETING ADAM9 AND METHODS OF USE OF THEM
|
|
WO2019222130A1
|
|
Combination treatment with antibody-drug conjugates and flt3 inhibitors
|
|
US2020048362A1
|
|
Methods of treatment using anti-erbb antibody-maytansinoid conjugates
|
|
KR20200108843A
|
|
Antibody drug conjugation, purification, and formulation method
|
|
TW201934549A
|
|
Benzodiazepine derivatives
|
|
TW201922294A
|
|
Combination treatment with antibody-drug conjugates and cytarabine
|
|
CN111372610A
|
|
Method for preventing oxidation of methionine in immunoconjugates
|
|
KR20200056396A
|
|
Separation of triple-light chain antibodies using cation exchange chromatography
|
|
SG11202001348WA
|
|
Methods for detection of folate receptor 1 in a patient sample
|
